Prostate Cancer Prevention by Pachymic Acid
Prostate Cancer Prevention by Pachymic Acid
批准号:
7116669
负责人:
LAWRENCE K NG
金额:
$11.61万
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-07-15 至 2007-06-30
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Prostate cancer is one of the most common malignancies and the second leading cause of cancer-related death in men in the United States. Progression of prostate cancer from its non-metastatic androgen-dependent phenotype to a more malignant metastatic androgen-independent phenotype is a slow and multi-step process that depends on both genetic and epigenetic factors. This slow progressing period provides a window for cancer prevention by intervention with compounds that interfere with specific stages of neoplastic progression. Poria cocos (P. Cocos) is a medicinal herb widely used in Asian countries for its sedative, diuretic, and tonic actions. Alcoholic extracts of P. cocos that are rich in lanostane-type triterpenoids have recently been shown to have anti-cancer and anti-inflammatory activities. However, the mechanism, efficacy, and safety of these triterpenoids in cancer treatment or prevention have not been systemically evaluated. Recently, in our preliminary experiments, we showed that extracts of P. cocos (PCE) (1) inhibit the growth of prostate cancer cells in vitro and in vivo (xenografts in nude mice) and (2) induce caspase-driven apoptosis in both androgen-dependent (LNCaP) and androgen-independent (DU145) human prostate carcinoma cells, indicating that triggering of apoptosis by PCE might occur independently of androgen responsiveness. The goals of this study are (1) to establish pachymic acid (PA), a triterpenoid and a major constituent of PCE, as a safe and effective anti-cancer agent for prostate cancer, and (2) to elucidate the potential molecular anticancer mechanism of PA. In particular, we will test the hypothesis that PA imparts cancer therapeutic and possibly cancer preventive effects by modulating the apoptotic machinery of prostate cancer cells via inhibition of phospholipase A2 (PLA2), removing potential downstream signals for AKT activation. To accomplish these objectives, we will employ LNCaP and DU145 prostate cancer cell lines to (1) determine the most effective and safe dose of PA for inhibition of cancer growth in nude mice with prostate cancer xenografts, and (2) define the molecular pathway through which PA induces prostate cancer cell apoptosis. Through this study, it is anticipated that the potential of PA as a novel and safe agent for treatment or prevention against prostate cancer will be identified.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Prostate Cancer Prevention by Pachymic Acid
-
批准号:6926020
-
项目类别:
-
资助金额:$4.76万
-
财政年份:2005
-
负责人:LAWRENCE K NG
-
依托单位:
Prostate Cancer Prevention by Pachymic Acid
-
批准号:7095118
-
项目类别:
-
资助金额:$8.85万
-
财政年份:2005
-
负责人:LAWRENCE K NG
-
依托单位:
BRAIN THERAPY USING ULTRASOUND MEDIATED DRUG DELIVERY
-
批准号:6350334
-
项目类别:
-
资助金额:$19.9万
-
财政年份:1999
-
负责人:LAWRENCE K NG
-
依托单位:
AEROSOL BASED NANOPARTICAL DRUG DELIVERY SYSTEM--TB
-
批准号:6537355
-
项目类别:
-
资助金额:$16.63万
-
财政年份:1999
-
负责人:LAWRENCE K NG
-
依托单位:
AEROSOL BASED NANOPARTICAL DRUG DELIVERY SYSTEM FOR TUBE
-
批准号:2842828
-
项目类别:
-
资助金额:$25.25万
-
财政年份:1999
-
负责人:LAWRENCE K NG
-
依托单位:
AEROSOL BASED NANOPARTICAL DRUG DELIVERY SYSTEM--TB
-
批准号:6183828
-
项目类别:
-
资助金额:$22.33万
-
财政年份:1999
-
负责人:LAWRENCE K NG
-
依托单位:
BRAIN THERAPY USING ULTRASOUND MEDIATED DRUG DELIVERY
-
批准号:6150354
-
项目类别:
-
资助金额:$20.44万
-
财政年份:1999
-
负责人:LAWRENCE K NG
-
依托单位:
AEROSOL BASED NANOPARTICAL DRUG DELIVERY SYSTEM--TB
-
批准号:6389787
-
项目类别:
-
资助金额:$22.46万
-
财政年份:1999
-
负责人:LAWRENCE K NG
-
依托单位:
BRAIN THERAPY USING ULTRASOUND MEDIATED DRUG DELIVERY
-
批准号:2731881
-
项目类别:
-
资助金额:$21.69万
-
财政年份:1999
-
负责人:LAWRENCE K NG
-
依托单位:
海外基金